BIIB Jan 2025 395.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 10:54AM EDT. Market open.
Loading interactive chart…
- Zacks
Biogen (BIIB) Partner Begins Filing for Leqembi SC Autoinjector
Biogen (BIIB) and Eisai start the rolling submission of a biologics license application to the FDA for Leqembi subcutaneous autoinjector as a weekly maintenance dosing regimen for early Alzheimer's disease.
- Investor's Business Daily
Is Eli Lilly Stock A Buy Or A Sell With Key Alzheimer's Meeting Looming?
Eli Lilly stock broke out and then retreated into sell-zone territory. With shares on the rise again, is LLY stock a buy?
- Investor's Business Daily
Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
Biogen stock jumped early Wednesday after the FDA gave its Eisai-partnered Alzheimer's treatment a fast track designation.
© 2024 Yahoo. All rights reserved.